TRAIL R2

TRAIL R2 Molekülinformation

Englischer Name	Tumor necrosis factor receptor superfamily member 10B	Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	10	Target-Alias	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Tumor necrosis factor receptor superfamily member 10B
Target-Alias	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
Anzahl der inverkehr gebrachten Arzneimittel	1
Anzahl der klinischen Arzneimittel	10
Höchste Forschungs- und Entwicklungsphase	Approved

TRAIL R2 Produktliste

Attribut
Protein (6)
Produktbibliothek
Online (6)
Spezies
Human (4)Mouse (1)Cynomolgus (1)
Etikett
His Tag (4)Fc Tag (1)His Tag & Avi Tag (1)
Marker
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT TR2-H5229	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin	In den Warenkorb legen
HOT TR2-H5255	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag, low endotoxin	In den Warenkorb legen
HOT TR2-H82E6	Human	HEK293	Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified)	In den Warenkorb legen
TR2-HF223	Human	HEK293	FITC-Labeled Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag	In den Warenkorb legen
TR2-M52H5	Mouse	HEK293	Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag	In den Warenkorb legen
TR2-C52H7	Cynomolgus	HEK293	Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin (MALS verified)	In den Warenkorb legen

Gesamtmenge6

Produktanfrage

TRAIL R2 Molekülhintergrund

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2 Molekülalias

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Dulanermin (Shanghai GeBaiDe)		Phase 3 Clinical	Shanghai Gebaide Biotechnology Co Ltd	Carcinoma, Non-Small-Cell Lung	Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)		Phase 3 Clinical	Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd	Neoplasms	Details
TLY-012	TLY-012	Phase 1 Clinical	Theraly Fibrosis	Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic	Details
BI-905711	BI-905711	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms	Details
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)	CTB-006	Phase 1 Clinical	Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd	Solid tumours	Details
Ozekibart	JCT-205; INBRX-109	Phase 1 Clinical	Inhibrx Inc	Adenocarcinoma	Details
TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Neoplasms	Details
RC-248	RC-248; RC248	Phase 1 Clinical		Solid tumours	Details
IBI-3004	IBI-3004; IBI3004	Phase 1 Clinical		Colorectal Neoplasms; Solid tumours	Details
Oba-01	Oba-01; Oba01	Phase 1 Clinical	Yantai Heyuanaidisi Biomedical Technology Co Ltd	Carcinoma, Non-Small-Cell Lung	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Aponermin		Approved	Beijing Shadong Biotech Co Ltd	沙艾特, Shaite	Mainland China	Multiple Myeloma	Wuhan Hiteck Biological Pharma Co Ltd	2023-11-02	Multiple Myeloma	Details